Insider Transactions in Q3 2025 at Bio Xcel Therapeutics, Inc. (BTAI)
Insider Transaction List (Q3 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2025
|
David J. Mack Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,694
+8.34%
|
-
|
|
Sep 15
2025
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
219
+1.06%
|
-
|
|
Sep 15
2025
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35
+0.55%
|
-
|
|
Sep 15
2025
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35
+0.52%
|
-
|
|
Sep 15
2025
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
35
+0.53%
|
-
|
|
Sep 14
2025
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
163
+0.8%
|
-
|
|
Sep 14
2025
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33
+0.52%
|
-
|
|
Sep 14
2025
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33
+0.49%
|
-
|
|
Sep 14
2025
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33
+0.51%
|
-
|
|
Aug 31
2025
|
David J. Mack Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,693
+9.09%
|
-
|
|
Jul 31
2025
|
David J. Mack Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,693
+10.0%
|
-
|
|
Jul 22
2025
|
Vimal Mehta CEO and President |
BUY
Grant, award, or other acquisition
|
Direct |
15,625
+43.72%
|
-
|
|
Jul 22
2025
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
625
+8.58%
|
-
|
|
Jul 22
2025
|
Javier Rodriguez Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,375
+42.03%
|
-
|
|
Jul 22
2025
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
625
+8.85%
|
-
|
|
Jul 22
2025
|
Richard I Steinhart Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,375
+42.93%
|
-
|
|
Jul 22
2025
|
Frank Yocca Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,375
+40.92%
|
-
|